ACM
BCAX

Aster Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Aster Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$17 – 1421
2025
Q4 		$17 Buy
+1
New +$17 ﹤0.01% 1053
2025
Q1 		– Sell
-77
Closed -$1.34K – 1739
2024
Q4 		$1.34K Sell
77
-645
-89% -$13.4K ﹤0.01% 999
2024
Q3 		$18.4K Buy
+722
New +$18.4K ﹤0.01% 699

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Aster Capital Management's BCAX Position: Q1 2026 in Review

Aster Capital Management sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 1 share — an estimated $17 sold.

Aster Capital Management first reported a position in BCAX in Q3 2024 and held it in 3 quarters. The position peaked at $18.4K in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Aster Capital Management reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 1 Bicara Therapeutics share in Q1 2026, an estimated $17.
  • Aster Capital Management first reported a position in Bicara Therapeutics in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's Bicara Therapeutics position peaked at $18.4K in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.